Publication plans. Journal articles. Conference abstracts. Investigator brochures. INDs. NDAs. BLAs. MSL slide decks. Scientific platforms. Educational materials for HCPs. Talk tracks. Visual Aids. Patient Education Brochures. Leave Behinds. Objection handlers. Sales Aids. Posters, E-blasts. Focus groups. Advisory boards.
Ask anyone in the pharmaceutical industry to identify a common thread among these and the answer will most likely lead to medical writing. Indeed, the ability to communicate scientific information to diverse audiences (regulatory bodies, researchers, health care providers, the general public, etc.) underpins the success of a pharma company’s development, regulatory and commercialization efforts. And ensuring strong, yet nimble, medical writing capabilities are available when called upon underpins the success of drug development companies, big and small.
However, there is another common thread among these items that may not be immediately apparent: they are frequently outsourced to multiple providers.
It is not uncommon for one vendor to handle pre-approval regulatory writing, another vendor to develop a scientific platform and publication plan, a third vendor to handle promotional and educational materials, and so forth. This “multi-vendor model” has been the preferred model for quite some time. However, a landscape shift is happening which will benefit not just medical writing vendors that rise to the challenge but, more importantly, the pharmaceutical companies that they serve – and ultimately patients.